Appl. No. 09/916,136 Amendment Dated December 2, 2003 Reply to Office Action of July 2, 2003

IN THE SPECIFICATION

At page 19, lines 5-15 (second paragraph) through page 22, lines 1-15, please amend Table I as follows:

TABLE I: Aldosterone Receptor Antagonist

Compound #


Structure and Name

1

Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ -lactone, methyl ester, $(7\alpha,11\alpha,17\beta\underline{\alpha})$ -

2

Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,dimethyl ester, $(7\alpha,11\alpha,17\beta\alpha)$ -



3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ -lactone,(6 β , 7 β , 11 α β , 17 β)-

4 OF THE STATE OF

Pregn-4-ene-7,21-dicarboxylic acid,9,11-epoxy-17-hydroxy-3-oxo-,7-(1-methylethyl) ester, monopotassium salt, $(7\alpha,11\alpha,17\beta\alpha)$ -

Pregn-4-ene-7,21-dicarboxylic acid,9,11-epoxy-17-hydroxy-3-oxo-,7-methylethyl) ester,monopotassium salt, $(7\alpha,11\alpha,17\beta\alpha)$ -


6

3'H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylicacid,9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-,


 γ -lactone (6 $\beta \alpha$, 7 $\beta \alpha$, 11 α) -

7

3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, methyl ester, $(6\beta\underline{\alpha},7\beta\underline{\alpha},11\alpha,17\beta\underline{\alpha})$ -




3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, $(6\beta\underline{\alpha},7\beta\underline{\alpha},11\alpha,17\beta\underline{\alpha})$ -



3'H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylicacid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-,γ-

lactone $(6\beta\alpha, 7\beta\alpha, 11\alpha, 17\beta\alpha)$ -



Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ -lactone, ethyl ester, $(7\alpha,11\alpha,17\beta\alpha)$ -

